Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Extensive data has been accumulated to suggest that central release of oxytocin is important
for social cognition and function, as well as likely involved in anxiety modulation and
repetitive behaviors. The principal investigators of this study have previously documented:
1) an association between Autism Spectrum Disorder and a single nuclear polymorphism of the
oxytocin receptor gene, 2) ability to measure oxytocin levels in the blood by enzyme
immunoassay and 3) preliminary data to support safety and efficacy of intranasal oxytocin in
the treatment of social deficits and repetitive behaviors in adults with autism. A medication
treatment targeting the core deficits of Autism Spectrum Disorder in childhood is highly
valuable because it could influence the developmental trajectory and make further
psychosocial interventions possible. In this context, we propose a small dose finding study
to confirm that the dose used in the adult study is not more than the maximum tolerated dose
in youth. '
Phase:
Phase 2
Details
Lead Sponsor:
Evdokia Anagnostou
Collaborators:
Holland Bloorview Kids Rehabilitation Hospital The Hospital for Sick Children University of Illinois at Chicago